Watch Ticker

Cognition Therapeutics, Inc. Common Stock

Go to Cognition Therapeutics, Inc. Common Stock Website

$1.98

(%)

Live

Previous Close

$1.98

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$76.1 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Cognition Therapeutics, Inc. - Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

- Top-line Results Expected in the Second Half of 2024 - - Top-line Results Expected in the Second Half of 2024 -

Related tickers: CGTX.

Read Full Article

Cognition Therapeutics, Inc. - Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, provided a recap of the virtual KOL event hosted on April 12, 2024 featuring Martin J. Sadowski, MD, PhD, DSci of the NYU School of Medicine; Anton Porsteinsson, MD of the University of Rochester Alzheimer's Disease Care, Research and Education Program; and Everard (Jort) Vijverberg, MD, PhD of the Alzheimer Center Amsterdam and Neuroscience Amsterdam.

Related tickers: CGTX.

Read Full Article

Trending Tickers

LASE

XNAS

$2.06

(%)

PACW

XNAS

$7.54

(%)

SMFL

XNAS

$3.32

(%)

XNYS

$70.30

(%)

MLGO

XNAS

$0.00

(%)